These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
176 related articles for article (PubMed ID: 33632561)
1. Pharmacological approach for the reduction of inflammatory and prothrombotic hyperactive state in COVID-19 positive patients by acting on complement cascade. Vitiello A; La Porta R; D'Aiuto V; Ferrara F Hum Immunol; 2021 Apr; 82(4):264-269. PubMed ID: 33632561 [TBL] [Abstract][Full Text] [Related]
2. New concepts on the therapeutic control of complement anaphylatoxin receptors. Hawksworth OA; Li XX; Coulthard LG; Wolvetang EJ; Woodruff TM Mol Immunol; 2017 Sep; 89():36-43. PubMed ID: 28576324 [TBL] [Abstract][Full Text] [Related]
3. Complement Inhibition in Coronavirus Disease (COVID)-19: A Neglected Therapeutic Option. Stahel PF; Barnum SR Front Immunol; 2020; 11():1661. PubMed ID: 32733489 [No Abstract] [Full Text] [Related]
4. Complement cascade in severe forms of COVID-19: Recent advances in therapy. Chouaki Benmansour N; Carvelli J; Vivier E Eur J Immunol; 2021 Jul; 51(7):1652-1659. PubMed ID: 33738806 [TBL] [Abstract][Full Text] [Related]
5. The case of complement inhibitors. Noris M Adv Biol Regul; 2021 Aug; 81():100822. PubMed ID: 34454870 [TBL] [Abstract][Full Text] [Related]
6. The Value of Targeting Complement Components in Asthma. Mohamed MME; Nicklin AD; Stover CM Medicina (Kaunas); 2020 Aug; 56(8):. PubMed ID: 32806638 [TBL] [Abstract][Full Text] [Related]
7. Implications of Complement Imbalance in COVID-19: A Molecular Mechanistic Discussion on the Importance of Complement Balance. Torabizadeh M; Modaresi Asfeh H; Deris Zayeri Z; Dominique C; Kazemi H; Saki N Iran J Immunol; 2023 Sep; 20(3):247-261. PubMed ID: 37545318 [TBL] [Abstract][Full Text] [Related]
8. Eculizumab-C5 complexes express a C5a neoepitope in vivo: Consequences for interpretation of patient complement analyses. Nilsson PH; Thomas AM; Bergseth G; Gustavsen A; Volokhina EB; van den Heuvel LP; Barratt-Due A; Mollnes TE Mol Immunol; 2017 Sep; 89():111-114. PubMed ID: 28610663 [TBL] [Abstract][Full Text] [Related]
9. A Phase 3 Open-label, Randomized, Controlled Study to Evaluate the Efficacy and Safety of Intravenously Administered Ravulizumab Compared with Best Supportive Care in Patients with COVID-19 Severe Pneumonia, Acute Lung Injury, or Acute Respiratory Distress Syndrome: A structured summary of a study protocol for a randomised controlled trial. Smith K; Pace A; Ortiz S; Kazani S; Rottinghaus S Trials; 2020 Jul; 21(1):639. PubMed ID: 32660611 [TBL] [Abstract][Full Text] [Related]
10. Blockade of the C5a-C5aR axis alleviates lung damage in hDPP4-transgenic mice infected with MERS-CoV. Jiang Y; Zhao G; Song N; Li P; Chen Y; Guo Y; Li J; Du L; Jiang S; Guo R; Sun S; Zhou Y Emerg Microbes Infect; 2018 Apr; 7(1):77. PubMed ID: 29691378 [TBL] [Abstract][Full Text] [Related]
12. Treatment of Rare Inflammatory Kidney Diseases: Drugs Targeting the Terminal Complement Pathway. Anliker-Ort M; Dingemanse J; van den Anker J; Kaufmann P Front Immunol; 2020; 11():599417. PubMed ID: 33362783 [TBL] [Abstract][Full Text] [Related]
13. Differential effects of complement activation products c3a and c5a on cardiovascular function in hypertensive pregnant rats. Lillegard KE; Loeks-Johnson AC; Opacich JW; Peterson JM; Bauer AJ; Elmquist BJ; Regal RR; Gilbert JS; Regal JF J Pharmacol Exp Ther; 2014 Nov; 351(2):344-51. PubMed ID: 25150279 [TBL] [Abstract][Full Text] [Related]
14. Mild Clinical Course of COVID-19 in 3 Patients Receiving Therapeutic Monoclonal Antibodies Targeting C5 Complement for Hematologic Disorders. Araten DJ; Belmont HM; Schaefer-Cutillo J; Iyengar A; Mattoo A; Reddy R Am J Case Rep; 2020 Sep; 21():e927418. PubMed ID: 32917848 [TBL] [Abstract][Full Text] [Related]
15. Complement C5 inhibition in patients with COVID-19 - a promising target? Peffault de Latour R; Bergeron A; Lengline E; Dupont T; Marchal A; Galicier L; de Castro N; Bondeelle L; Darmon M; Dupin C; Dumas G; Leguen P; Madelaine I; Chevret S; Molina JM; Azoulay E; Fremeaux-Bacchi V; Core Group Haematologica; 2020 Dec; 105(12):2847-2850. PubMed ID: 33256385 [No Abstract] [Full Text] [Related]
18. COVID-19: A collision of complement, coagulation and inflammatory pathways. Chauhan AJ; Wiffen LJ; Brown TP J Thromb Haemost; 2020 Sep; 18(9):2110-2117. PubMed ID: 32608159 [TBL] [Abstract][Full Text] [Related]
19. [Involvement of the complement cascade in severe forms of COVID-19]. Chouaki Benmansour N; Carvelli J; Vivier É Med Sci (Paris); 2021 Apr; 37(4):333-341. PubMed ID: 33835019 [TBL] [Abstract][Full Text] [Related]
20. Complement as a target in COVID-19? Risitano AM; Mastellos DC; Huber-Lang M; Yancopoulou D; Garlanda C; Ciceri F; Lambris JD Nat Rev Immunol; 2020 Jun; 20(6):343-344. PubMed ID: 32327719 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]